clinical trial · NCT05901649
A Study for the Participants With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Treated With Androgen Deprivation Therapy (ADT) Plus Apalutamide or Enzalutamide
Metastatic Hormone-sensitive Prostate CancerApalutamideEnzalutamide
brief summary
The purpose of this study is to assess the real-world outcomes differences between apalutamide or enzalutamide plus androgen deprivation therapy (ADT) for the treatment of participants with metastatic hormone-sensitive prostate cancer (mHSPC).
started
Jul 5, 2023
primary completion
Jun 5, 2026
completion
Jun 5, 2026
last updated
May 8, 2026
official title
Prospective, Multi-Country, Observational Study of Clinical Outcomes for Participants With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Treated With ADT Plus Apalutamide or Enzalutamide Under Routine Clinical Practice (ArtemisPRO)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol